Addendum to Systematic Review of Remdesivir for the Treatment of COVID-19

Musa, Arif; Warbasse, Elizabeth; Baron, David; Pendi, Kasim; Hashemi, Areio; Yousif, Jenna; Blodget, Emily; Stevens, Susan; Aly, Besma; Khambati, Alisha; Kouyoumjian, Sarkis

doi:10.5811/westjem.2020.5.48121

Cited by 2 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 19 Concurrent in vitro research has supported the use of the drug to treat SARS-CoV-2 infections. 20 In contrast, Zhang et al have raised concerns about the possibility of unknown adverse reactions. 8 …”

Section: Discussionmentioning

confidence: 99%

Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature

Musa

Pendi

Hashemi

et al. 2020

WestJEM

Self Cite

View full text Add to dashboard Cite

In March 2020, the World Health Organization declared the spread of SARS-CoV-2 a global pandemic. To date, coronavirus disease-2019 (COVID-19) has spread to over 200 countries, leading to over 1.6 million cases and over 99,000 deaths. Given that there is neither a vaccine nor proven treatment for COVID-19, there is currently an urgent need for effective pharmacotherapy. To address the need for an effective treatment of SARS-CoV-2 during the worldwide pandemic, this systematic review of intravenous (IV) remdesivir was performed. Remdesivir, an anti-viral prodrug originally developed to treat Ebola virus disease, has shown broad spectrum activity against the Coronavirus family. A recent case report reported improvement of clinical symptoms with remdesivir in a patient with COVID-19. After conducting a systematic search of 18 clinical trial registries and three large scientific databases, we identified 86 potentially eligible items. Following removal of duplicates (n = 21), eligible studies were reviewed independently by two authors. After the first round of screening, inter-rater agreement was 98.5% (κ = 0.925). After the second round of full-text screening, inter-rater agreement was 100%. A total of seven ongoing and recruiting clinical trials of remdesivir (100–200 milligrams, intravenous [IV]) were included. We identified the following primary outcomes: patients discharged (n = 2); time to clinical status improvement (n = 2); improved O2 saturation (n = 2); body temperature normalization (n = 2); and clinical status (n = 1). Secondary outcomes in all identified studies included documentation of adverse events. Phase 3 trials are expected to be completed between April 2020–2023. Therefore, despite supportive data from in vitro and in vivo studies, the clinical effectiveness of IV remdesivir for treatment of COVID-19 and potential side effects remain incompletely defined in the human population.

show abstract

Section: Discussionmentioning

confidence: 99%

Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature

Musa

Pendi

Hashemi

et al. 2020

WestJEM

Self Cite

View full text Add to dashboard Cite

show abstract

Recent Advances in Understanding SARS-CoV-2 Infection and Updates on Potential Diagnostic and Therapeutics for COVID-19

Verma

Yadav

Chaudhary

et al. 2022

COVID

View full text Add to dashboard Cite

A more focused approach is needed to understand the SARS-CoV-2 virulence, structure, and genomics to devise more effective diagnostic and treatment interventions as this virus can evade the immune attack and causes life threading complications such as cytokine storm. The spread of the virus is still amplifying and causing thousands of new cases worldwide. It is important to review current diagnostics and treatment approaches to pave the way to correct or modify our current approaches to make more effective interventions against COVID-19. COVID-19 vaccine development has moved at a breakneck pace since the outbreak began, utilizing practically all possible platforms or tactics to ensure the success of vaccines. A total of 42 vaccine candidates already have entered clinical trials, including promising results from numerous vaccine candidates in phase 1 or phase 2 trials. Further, many existing drugs are being explored on broad-spectrum antiviral medications for their use in clinical recovery against COVID-19. The present review attempts to re-examine SARS-CoV-2 structure, its viral life cycle, clinical symptoms and pathogenesis, mode of transmission, diagnostics and treatment strategies that may be useful for resorting to more effective approaches for controlling COVID-19. Various antiviral drugs and vaccination strategies with their strengths and weaknesses are also discussed in the paper to augment our understanding of COVID-19 management.

show abstract

Addendum to Systematic Review of Remdesivir for the Treatment of COVID-19

Cited by 2 publications

References 4 publications

Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature

Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature

Recent Advances in Understanding SARS-CoV-2 Infection and Updates on Potential Diagnostic and Therapeutics for COVID-19

Contact Info

Product

Resources

About